The 1st SGLT2i also licensed to treat
diabetic kidney disease (DKD) in T2DM
Now for treatment of patients with severe albuminuria from
early identification until dialysis or renal transplantation
1st
Watch the animation below on the first published renal outcomes study with an SGLT2i. 1
The CREDENCE trial and its value from a clinical perspective
David Wheeler, Professor of Kidney Medicine, University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust looks at the findings of the CREDENCE study and the impact of Invokana on the progression of chronic kidney disease (CKD) and cardiovascular complications in patients with both type 2 diabetes and CKD.
Professor John Wilding, Professor of Endocrinology at the University of Liverpool, and Honorary Consultant Diabetologist, University Hospital, Aintree discusses the CREDENCE study, and how Invokana has emerged as first new treatment to reduce the progression of chronic kidney disease in type 2 diabetes for 20 years.
Professor Philip Kalra, Consultant Nephrologist at Salford Royal Foundation Trust, Manchester and Professor John Wilding, Professor of Endocrinology at the University of Liverpool, and Honorary Consultant Diabetologist, University Hospital, Aintree present their key take home messages from the CREDENCE trial.
Julie Brake, Diabetes Nurse Consultant, Royal Liverpool University Hospital NHS Trust, and Professor Philip Kalra, Consultant Nephrologist at Salford Royal Foundation Trust, Manchester discuss the clinical value of the CREDENCE study and implications for patients with type 2 diabetes and chronic kidney disease.
Protect T2DM patients against diabetic kidney disease (DKD) progression
In CREDENCE, Invokana showed a:
Reduce future kidney damage and slow the decline of kidney function
In CREDENCE, Invokana showed a:
References
- Reference 16
- Reference 7
